Epigenetic control of cancer by neuropeptides (Review)

Karina Galoian, Parthik Patel

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Neuropeptides act as neurohormones, neurotrans-mitters and/or neuromodulators. Neuropeptides maintain physiological homeostasis and are paramount in molecular mechanisms of disease progression and regulation, including in cancer. Neuropeptides, by their definition, originate and are secreted from the neuronal cells, they are able to signal to neighboring cells or are released into the blood flow, if they act as neurohormones. The majority of neuropeptides exert their functions through G protein-coupled receptors, with certain exceptions. Although previous studies indicate that neuropeptides function in supporting proliferation of malig�nant cells in many types of solid tumor, the antitumorigenic action of the neuropeptides and their receptors, for example, in gastric cancers and chondrosarcoma, were also reported. It is known that epigenetically modified chromatin regulates molecular mechanisms involved in gene expression and malignant progression. The epigenetic modifications are genetically heritable, although they do not cause changes in DNA sequence. DNA methylation, histone modifications and miRNA expression are subject to those modifications. While there is substantial data on epigenetic regulation of neuropeptides, the epigenetic control of cancer by neuropeptides is considered to be uncharted territory. The aim of the current review is to describe the involvement of neuropeptides in the epigenetic machinery of cancer based on data obtained from our laboratory and from other authors.

Original languageEnglish (US)
Pages (from-to)3-7
Number of pages5
JournalBiomedical Reports
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Neuropeptides
Epigenomics
Neoplasms
Neurotransmitter Agents
Histone Code
Neuropeptide Receptors
Chondrosarcoma
DNA sequences
DNA Methylation
G-Protein-Coupled Receptors
MicroRNAs
Gene expression
Histones
Stomach Neoplasms
Chromatin
Machinery
Disease Progression
Tumors
Homeostasis
Blood

Keywords

  • Cancer
  • Epigenetics
  • Gastrin
  • Neuropeptides
  • Neurotensin
  • Pituitary adenylate cyclase‑activating polypeptide
  • Proline‑rich polypeptide‑1
  • Vasoactive intestinal peptide

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Epigenetic control of cancer by neuropeptides (Review). / Galoian, Karina; Patel, Parthik.

In: Biomedical Reports, Vol. 6, No. 1, 01.01.2017, p. 3-7.

Research output: Contribution to journalReview article

Galoian, Karina ; Patel, Parthik. / Epigenetic control of cancer by neuropeptides (Review). In: Biomedical Reports. 2017 ; Vol. 6, No. 1. pp. 3-7.
@article{d8411241617441628091ca8e2c9bd1bc,
title = "Epigenetic control of cancer by neuropeptides (Review)",
abstract = "Neuropeptides act as neurohormones, neurotrans-mitters and/or neuromodulators. Neuropeptides maintain physiological homeostasis and are paramount in molecular mechanisms of disease progression and regulation, including in cancer. Neuropeptides, by their definition, originate and are secreted from the neuronal cells, they are able to signal to neighboring cells or are released into the blood flow, if they act as neurohormones. The majority of neuropeptides exert their functions through G protein-coupled receptors, with certain exceptions. Although previous studies indicate that neuropeptides function in supporting proliferation of malig{\"i}¿½nant cells in many types of solid tumor, the antitumorigenic action of the neuropeptides and their receptors, for example, in gastric cancers and chondrosarcoma, were also reported. It is known that epigenetically modified chromatin regulates molecular mechanisms involved in gene expression and malignant progression. The epigenetic modifications are genetically heritable, although they do not cause changes in DNA sequence. DNA methylation, histone modifications and miRNA expression are subject to those modifications. While there is substantial data on epigenetic regulation of neuropeptides, the epigenetic control of cancer by neuropeptides is considered to be uncharted territory. The aim of the current review is to describe the involvement of neuropeptides in the epigenetic machinery of cancer based on data obtained from our laboratory and from other authors.",
keywords = "Cancer, Epigenetics, Gastrin, Neuropeptides, Neurotensin, Pituitary adenylate cyclase‑activating polypeptide, Proline‑rich polypeptide‑1, Vasoactive intestinal peptide",
author = "Karina Galoian and Parthik Patel",
year = "2017",
month = "1",
day = "1",
doi = "10.3892/br.2016.804",
language = "English (US)",
volume = "6",
pages = "3--7",
journal = "Biomedical Reports",
issn = "2049-9434",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Epigenetic control of cancer by neuropeptides (Review)

AU - Galoian, Karina

AU - Patel, Parthik

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Neuropeptides act as neurohormones, neurotrans-mitters and/or neuromodulators. Neuropeptides maintain physiological homeostasis and are paramount in molecular mechanisms of disease progression and regulation, including in cancer. Neuropeptides, by their definition, originate and are secreted from the neuronal cells, they are able to signal to neighboring cells or are released into the blood flow, if they act as neurohormones. The majority of neuropeptides exert their functions through G protein-coupled receptors, with certain exceptions. Although previous studies indicate that neuropeptides function in supporting proliferation of malig�nant cells in many types of solid tumor, the antitumorigenic action of the neuropeptides and their receptors, for example, in gastric cancers and chondrosarcoma, were also reported. It is known that epigenetically modified chromatin regulates molecular mechanisms involved in gene expression and malignant progression. The epigenetic modifications are genetically heritable, although they do not cause changes in DNA sequence. DNA methylation, histone modifications and miRNA expression are subject to those modifications. While there is substantial data on epigenetic regulation of neuropeptides, the epigenetic control of cancer by neuropeptides is considered to be uncharted territory. The aim of the current review is to describe the involvement of neuropeptides in the epigenetic machinery of cancer based on data obtained from our laboratory and from other authors.

AB - Neuropeptides act as neurohormones, neurotrans-mitters and/or neuromodulators. Neuropeptides maintain physiological homeostasis and are paramount in molecular mechanisms of disease progression and regulation, including in cancer. Neuropeptides, by their definition, originate and are secreted from the neuronal cells, they are able to signal to neighboring cells or are released into the blood flow, if they act as neurohormones. The majority of neuropeptides exert their functions through G protein-coupled receptors, with certain exceptions. Although previous studies indicate that neuropeptides function in supporting proliferation of malig�nant cells in many types of solid tumor, the antitumorigenic action of the neuropeptides and their receptors, for example, in gastric cancers and chondrosarcoma, were also reported. It is known that epigenetically modified chromatin regulates molecular mechanisms involved in gene expression and malignant progression. The epigenetic modifications are genetically heritable, although they do not cause changes in DNA sequence. DNA methylation, histone modifications and miRNA expression are subject to those modifications. While there is substantial data on epigenetic regulation of neuropeptides, the epigenetic control of cancer by neuropeptides is considered to be uncharted territory. The aim of the current review is to describe the involvement of neuropeptides in the epigenetic machinery of cancer based on data obtained from our laboratory and from other authors.

KW - Cancer

KW - Epigenetics

KW - Gastrin

KW - Neuropeptides

KW - Neurotensin

KW - Pituitary adenylate cyclase‑activating polypeptide

KW - Proline‑rich polypeptide‑1

KW - Vasoactive intestinal peptide

UR - http://www.scopus.com/inward/record.url?scp=85026355358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026355358&partnerID=8YFLogxK

U2 - 10.3892/br.2016.804

DO - 10.3892/br.2016.804

M3 - Review article

AN - SCOPUS:85026355358

VL - 6

SP - 3

EP - 7

JO - Biomedical Reports

JF - Biomedical Reports

SN - 2049-9434

IS - 1

ER -